NCT05284175View on ClinicalTrials.gov

A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

NAUnknownINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

April 30, 2022

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions

Neuromyelitis Optica Spectrum Disorder

Interventions

DRUG

Orelabrutinib

Orelabrutinib, orally, 50 mg QD

Trial Locations (1)

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors

Collaborators (1)

GCP ClinPlus Co., Ltd.

All Listed Sponsors

collaborator

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY

collaborator

GCP ClinPlus Co., Ltd.

UNKNOWN

lead

Peking Union Medical College Hospital

OTHER

NCT05284175 - A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder | Biotech Hunter | Biotech Hunter